FDA puts off social-media rules again; Dainippon nabs European rights to Latuda;

 @FiercePharma: GSK partner holds off generic rival for Lovaza. News | Follow @FiercePharma

> The FDA has once again postponed the release of its first draft guidance for pharma's use of social media. Report

> Dainippon Sumitomo inked a licensing deal that gives Takeda Pharmaceutical exclusive marketing rights to its antipsychotic drug Latuda in most of Europe, the Nikkei business daily reported. Report

> Sanofi-Aventis lost a bid to dismiss a U.S. lawsuit launched by an investor for allegedly withholding information on its flopped anti-obesity pill Acomplia, which was once seen as a potential blockbuster. News

> Par Pharmaceutical reached a $1.7 million settlement with the state of Idaho to resolve a dispute over inflated wholesale drug prices. Story

> Lundbeck, the Danish drugmaker that unwittingly has become a key supplier of an execution drug in the U.S., says it's not going to withdraw or restrict it, even though it objects to the chemical's being misused for capital punishment. News

> Celebrities signing on as spokespeople for branded pharmaceuticals is nothing new, but now generics maker Genmed Holding has hired actor Eric Roberts for a promotional campaign. Article

> India's Aurobindo Pharma said it has received final approval from the FDA to manufacture and sell a generic version of Bristol-Myers Squibb's Monpril blood pressure. Article

> Aurobindo Pharma also got the FDA nod for its version of the Ortho McNeil Janssen Alzheimer's remedy Razadyne. Item

Biotech News

 @FierceBiotech: Ariad CEO vows that company "is not for sale." Article | Follow @FierceBiotech 

 @JohnCFierce: Doctors are clearly eager to get their hands on telaprevir and boceprevir, which bodes well for Vertex and Merck. Story | Follow @JohnCFierce 

> Valeant vows to restructure Cephalon as it moves in for the kill. Report

> RNAi pioneer RXi lands Ph3 cancer vax in Apthera buyout. Item

Vaccines News

> Interview: VaxInnate plots its future following HHS contact. Article

> FDA approves Merck's Zostavax for more adults. Report

> Gates funds two Indian vaccine firms. Story

> Pfizer's Prevnar and Sanofi's ActHIB cleared for Japanese market. News

Manufacturing News

> Indian officials trip over 2D tracking codes. Story

> GSK plies savings from green initiatives. News

> AZ, BMS, Lilly, Pfizer make investor's cut. Report

> Worker deaths probed at Dr. Reddy's plants. Article

> Pallet-maker war goes public. Article

And Finally... A family of blood cancer drugs made by Merck and Novartis may help treat a rare and incurable disease that causes large tumors to form in the chest, head and neck of children, Harvard researchers report. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.